October 22, 2024
Mayer Brown advises SERB Pharmaceuticals on the structuring of the acquisition of Aurlumyn®
Related People:
Mayer Brown advised SERB Pharmaceuticals, a global specialty pharmaceutical company, on the structuring of the acquisition of Aurlumyn ®(iloprost IV), the only FDA approved treatment option for severe frostbite in the US, from CiVi Biopharma.
Authors
Stay Up To Date With Our Insights
See how we use a multidisciplinary, integrated approach to meet our clients' needs.
Subscribe